TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00633880

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: 100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
Study: NCT02102607

Intervention type: OTHER
Intervention: age
Description: subjects stratified according to age: 20-30 years (Group 1), 31-40 years (Group 2), 41-50 years (Group 3), 51-60 years (Group 4), 61-70 years (Group 5), and 71-80 years (Group 6).
Study: NCT02729883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete interviews

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Receive patient navigation via the Take the Fight strategists
Study: NCT03667976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SATHI
Description: see above
Study: NCT02336867

Intervention type: DEVICE
Group type: OTHER
Intervention: Closure clip (OTSC® Proctology)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closure clip (OTSC® Proctology)
Study: NCT00583908

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens
Study: NCT00301938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7-hydroxystaurosporine
Description: Given IV
Study: NCT00583908

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A toric
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A toric
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A toric
Description: toric contact lens
Study: NCT00301938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7-hydroxystaurosporine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perifosine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perifosine
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT05703906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation - VRRS Khymeia
Description: Participants will receive an individualized, multidomain exercise program set up by the therapist, based on their needs. The intervention applied will consist of 20 sessions of motor, language and/or cognitive training distributed in five sessions for week, each lasting 1 hour. Remotely, the therapist will supervise the participant's exercise program.
Study: NCT00583908

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A toric
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A toric
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A toric
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A toric
Description: toric contact lens
Study: NCT00929942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SX-ELLA Stent Degradable DV Bronchial (DV Stent)
Description: Intervention SX-ELLA Stent Degradable DV Bronchial (DV Stent) will be implanted in the target lesion in general anesthesia under fluoroscopy or by direct vision. Before dilatation, extension of the airway complications will be measured by bronchoscopy and documented.
Study: NCT00583908

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A toric
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A toric
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A toric
Description: toric contact lens
Study: NCT03349502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG4101
Description: Administration of study drug (MG4101) for the patients with refractory or relapsed acute myeloid leukemia (Single arm)
Study: NCT01868425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multimodal:acetaminophen, gabapentin, ketamine, bupivacaine
Description: acetaminophen, gabapentin, ketamine, bupivacaine and standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo pills and injectables
Description: receives standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane plus placebos of intervention arm meds
Study: NCT03863015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab 20 Mg/mL Intravenous Solution
Description: Tocilizumab is suspended in isotonic saline to a total volume of 100mL prior to infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline
Description: A one hour infusion of 100mL isotonic saline
Study: NCT02271360

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Dobesilate
Description: 1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given at day of HCG injection and for 21 days
Study: NCT00583908

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A toric
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A toric
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B toric
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B toric
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B toric
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B toric
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B toric
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B toric
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B toric
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B toric
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B toric
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B toric
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B toric
Description: toric contact lens
Study: NCT02271360

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabergoline
Description: 1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days
Study: NCT03807960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: written form
Description: The written form which include PCA usage information.
Study: NCT00583908

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B toric
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens
Study: NCT03807960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video
Description: The video about PCA usage
Study: NCT00583908

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens
Study: NCT03807960

Intervention type: OTHER
Group type: OTHER
Intervention: routine care
Description: The routine description about PCA usage
Study: NCT00749957

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2-CB-hRPE65
Description: Recombinant adeno-associated virus vector expressing RPE65

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2-CB-hRPE65
Description: Recombinant adeno-associated virus vector expressing RPE65
Study: NCT00583908

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens
Study: NCT03582787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath MAC videolaryngoscopy
Description: Orotracheal intubation with McGrath MAC videolaryngoscopy after anesthetic induction
Study: NCT03582787

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Macintosh Laryngoscopy
Description: Orotracheal intubation with Macintosh Laryngoscopy after anesthetic induction
Study: NCT04531098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sci-B-Vac-Lot B
Description: Sci-B-Vac Lot B -10 μg of HBsAg, intramuscular injection of 10 μg/ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sci-B-Vac-Lot A
Description: Sci-B-Vac Lot A - 10 μg of HBsAg, intramuscular injection of 10 μg/ml

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: Engerix-B (hepatitis B vaccine (recombinant)) is indicated for active immunization against hepatitis B virus infection
Study: NCT02553642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Monotherapy Treatment - Nivolumab 240 mg flat dose Dosed q 2 weeks~OR~- Nivolumab 480 mg flat dose Dosed q 4 weeks~for up to 2 years from 1st dose of nivolumab or until loss of clinical benefit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab
Description: Combination Treatment~* Ipilimumab 3 mg/kg~* Nivolumab 1 mg/kg Dosed q 3 weeks x 4 doses
Study: NCT01018758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Palonosetron will be given as an intravenous bolus at the dose of 250 micrograms over 30 seconds beginning 30 minutes before chemotherapy.
Study: NCT03178370

Intervention type: DEVICE
Intervention: Gastric Electrical Stimulation
Description: Temporary and permanent gastric electrical stimulation

Intervention type: DEVICE
Intervention: Gastric Electrical Stimulation
Description: Temporary and permanent gastric electrical stimulation
Study: NCT01589367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin HCl 500mg(morning/evening) PO daily x 1week Metformin HCl 1000mg(morning)and 500mg(evening)PO daily x 1week Metformin HCl 1000mg(morning/evening) PO daily x 22weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Letrozole 2.5mg PO daily + Placebo 1 tablet PO 2/day x 1week Letrozole 2.5mg PO daily + Placebo 2 tablet+ 1 tablet PO x 1 week Letrozole 2.5mg PO daily + Placebo 2 tablet PO 2/day x 22 weeks
Study: NCT01059773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Patients weighting ≤ 100 kg will receive ustekinumab 45 mg at Weeks 0, 4 and 16. Patients who achieve a PASI 75 response at Week 28 and 40 will continue receiving ustekinumab 45 mg at Week 28 and 40. Patients who fail to achieve PASI 75 response at Week 28 will receive ustekinumab 90 mg at Week 28 and 40. Patients who achieve a PASI 75 response at Week 28, but fail to achieve PASI 75 response at Week 40 will receive ustekinumab 90 mg at Week 40. Patients \> 100 kg will receive ustekinumab 90 mg at Weeks 0, 4, 16, 28 and 40, regardless of achievement of PASI 75 response. Consideration will be given to discontinuing treatment in these patients if they show no response at Week 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Patients weighting ≤ 100 kg will receive ustekinumab 45 mg at Weeks 0, 4 and 16. Patients who achieve a PASI 75 response at Week 28 and 40 will continue receiving ustekinumab 45 mg at Week 28 and 40. Patients who fail to achieve PASI 75 response at Week 28 will receive ustekinumab 90 mg at Week 28 and 40. Patients who achieve a PASI 75 response at Week 28, but fail to achieve PASI 75 response at Week 40 will receive ustekinumab 90 mg at Week 40. Patients \> 100 kg will receive ustekinumab 90 mg at Weeks 0, 4, 16, 28 and 40, regardless of achievement of PASI 75 response. Consideration will be given to discontinuing treatment in these patients if they show no response at Week 28.
Study: NCT01714661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6124
Description: Arms 1, 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6124
Description: Arms 1, 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm 3
Study: NCT01059773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Gradual reduction of methotrexate therapy over the 4 week period after Week 0. The methotrexate dose reduction regime will depend on the dose of methotrexate at screening. All patients will stop methotrexate regardless of the final dose after 4 overlapping weeks. The last dose of methotrexate will be given within the 7 day period before the second dose of ustekinumab.
Study: NCT01934348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological First Aid

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual victim advocacy Services
Study: NCT06307717

Intervention type: DRUG
Intervention: volatile anaesthetic (sevoflurane, isoflurane, desflurane)
Description: Patients receiving volatile anaesthetics received at least one volatile anaesthetic (sevoflurane, isoflurane, desflurane), and those who received non-volatile anaesthetics did not receive any volatile anaesthetic.
Study: NCT03339232

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: BCAA Supplement
Description: Each teaspoon contains 1788 mg of BCAA and participants will take 7 teaspoons (12.5 grams of BCAA) per day divided into three separate servings. Each teaspoon contains L-leucine, isoleucine and valine in a 2:1:1 ratio.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: BCAA Supplement
Description: Each teaspoon contains 1788 mg of BCAA and participants will take 7 teaspoons (12.5 grams of BCAA) per day divided into three separate servings. Each teaspoon contains L-leucine, isoleucine and valine in a 2:1:1 ratio.

Intervention type: OTHER
Group type: OTHER
Intervention: Physical Activity
Description: Supervised low impact aerobic physical activity for one hour each week.
Study: NCT00413205

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAR Gamma
Description: 5mg po daily
Study: NCT00644163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eban HIV/STD Risk Reduction Intervention
Description: The eight-session Eban HIV/STD Risk Reduction Intervention is embedded in a cultural context and is gender tailored in its prevention messages and activities. Sessions will focus on the couple and will teach the couple about communication skills. The approach will draw upon social cognitive theory, an ecological framework, and HIV/STD risk-reduction research with inner-city African-American populations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eban Health Promotion Intervention
Description: The eight-session Eban Health Promotion Intervention is guided by a social cognitive approach that engages health promotion skills. Sessions will focus on the individual and will provide factual information on health, screening, exercise, diet management, and medication adherence.
Study: NCT02248064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-titrating oxygen system
Description: The auto-titrating oxygen system contains a number of components working together to produce variable oxygen flow. An oximeter measures the oxygen saturation of a patient and via Bluetooth this is relayed to a control centre in a mobile phone. This in turn regulates a flow meter which adjust oxygen flow.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-titrating oxygen system
Description: The auto-titrating oxygen system contains a number of components working together to produce variable oxygen flow. An oximeter measures the oxygen saturation of a patient and via Bluetooth this is relayed to a control centre in a mobile phone. This in turn regulates a flow meter which adjust oxygen flow.
Study: NCT01526785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alglucosidase alfa
Description: 4000 L alglucosidase alfa administered by IV infusion at the same dose and dose regimen used for the patient's routine treatment prior to the study for 52 weeks.
Study: NCT00746226

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus acidophilus and Bifidobacterium lactis
Description: Daily 5x10\^9 CFU of a combination of L. acidophilus and B. lactis

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose~As capsule which could be opened
Study: NCT02842476

Intervention type: DEVICE
Intervention: Disposable Sensor
Description: Two adhesive based Pulse Oximeter Probes, S0136J-L were connected to the Cadwell Pulse Oximetry and then placed on each subject to evaluate the SpO2 accuracy performance during steady state non-motion conditions.

Intervention type: DEVICE
Intervention: Reusable Sensor
Description: Two soft reusable Pulse Oximeter Probes, Model S0080D-S were connected to the Cadwell Pulse Oximetry and then placed on each subject to evaluate the SpO2 accuracy performance during steady state non-motion conditions.

Intervention type: DEVICE
Intervention: Control Pulse Oximetry
Description: A Clinimark Control Pulse Oximetry system was also placed on the subject to evaluate the stability of the draws.
Study: NCT05952921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouthwash
Description: Concentration rinse with 0.05% HOCl

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: A high concentration of 0.2% CHX (7 days), followed by 0.012% CHX (14 days).
Study: NCT02871141

Intervention type: PROCEDURE
Intervention: electroconvulsive therapy
Description: electroconvulsive therapy

Intervention type: DRUG
Intervention: Antidepressant
Description: Antidepressant
Study: NCT00268983

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tositumomab and Iodine I 131 Tositumomab
Description: Dosimetric dose: 450 mg Tositumomab infused over 1 hour followed by 5 mCi I 131 Tositumomab infused over 20 minutes~Therapeutic dose: 450 mg Tositumomab infused over 1 hour followed by Individualized mCi activity of I 131 Tositumomab (35 mg) infused over 20 minutes.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375 mg/m2 given as an IV infusion once weekly for four weeks.
Study: NCT00887614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
Study: NCT02874612

Intervention type: OTHER
Intervention: Psychosocial Survey Questionnaires
Description: Young adults with Type 1 Diabetes Mellitus will be invited to participate in a observational study in which they complete psychosocial measures immediately after completing a readiness transition survey and then again 1 year later.
Study: NCT01064414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One matching placebo capsule orally once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information